Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging Tumor-Agnostic Molecular Targets.

Molecular cancer therapeutics - 4 Nov 2024

Bhamidipati Dedipya, Schram Alison M

Abstract excerpt

Advances in tumor molecular profiling have uncovered shared genomic and proteomic alterations across tumor types that can be exploited therapeutically. A biomarker-driven, disease-agnostic approach to oncology drug development can maximize the reach of novel therapeutics. To date, eight drug-biomarker pairs have been approved for the treatment of patients with advanced solid tumors with specific molecular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor
Share to FGFR1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to FGFR2 gene

Share to NRG1 gene

Share to Molecular Targeted Therapy

Share to Mutation

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 39279103
DOI: 10.1158/1535-7163.MCT-23-0725
PMCID: PMC11908425

Genes

BRAF
ALK
FGFR1
FGFR2
KRAS
NRG1
TP53

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging Tumor-Agnostic Molecular Targets.PMID 39279103Read ↗

[Histology-agnostic tumor treatment - a farewell to tumor entities?]Semantic proximity Read ↗

Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.Semantic proximity Read ↗

Harnessing tumor-agnostic biomarkers for precision medicine in lymphoma.Semantic proximity Read ↗

Pan-Cancer Biomarkers: Changing the Landscape of Molecular Testing.Semantic proximity Read ↗

Special report: multiple molecular testing of cancers to identify targeted therapies.Semantic proximity Read ↗

Target-Driven Tissue-Agnostic Drug Approvals; a New Path of Drug DevelopmentSemantic proximity Read ↗

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.Semantic proximity Read ↗

Impact of tissue-agnostic approvals for patients with gastrointestinal malignanciesSemantic proximity Read ↗

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right GenomicsSemantic proximity Read ↗

Tissue-Agnostic Drug Development: A New Path to Drug ApprovalSemantic proximity Read ↗

Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles.Semantic proximity Read ↗

Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.